- Home
- TJGC vs ANEB Comparison
TJGC vs ANEB Comparison
Compare TJGC & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TJGC | ANEB |
|---|---|---|
| Founded | 2022 | 2020 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0M | 19.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TJGC | ANEB |
|---|---|---|
| Price | $0.85 | $0.36 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 85.3K | ★ 94.4K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.77 | $0.35 |
| 52 Week High | $1.55 | $3.42 |
Technical Indicators
Market Signals| Indicator | TJGC | ANEB |
|---|---|---|
| Relative Strength Index (RSI) | 41.43 | 17.01 |
| Support Level | N/A | N/A |
| Resistance Level | $1.16 | $0.51 |
| Average True Range (ATR) | 0.11 | 0.05 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 17.10 | 0.05 |
Price Performance
Historical ComparisonAbout TJGC TJGC Group Limited Ordinary Shares
TJGC Group Ltd, formerly CTRL Group Ltd is an integrated marketing and advertising services provider in Hong Kong specializing in mobile games promotion for the local market. It provide services to mobile game developers, principally developers of mobile gaming applications or apps that gamers download from the developers' websites and applicable mobile operating systems, such as Apple Store or Android Google Play Store.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.